# Effect of Renal Impairment on the Pharmacokinetics of NN9535

> **NCT00833716** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 62 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2
- Renal Impairment

## Interventions

- **DRUG:** semaglutide

## Key facts

- **NCT ID:** NCT00833716
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02-02
- **Primary completion:** 2010-07-26
- **Final completion:** 2010-07-26
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833716, "Effect of Renal Impairment on the Pharmacokinetics of NN9535". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00833716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*